MZT - nee Matritech - joins Inverness:
This article was originally published in Clinica
Inverness Medical Innovations has completed its acquisition of Newton, Massaschusetts-based cancer diagnostics developer Matritech. On the closing of the transaction, Matritech has changed its name to MZT Holdings and will be shortly seeking a delisting from the American Stock Exchange. Inverness, through its newly-formed subsidiary Milano Acquisitions, purchased all assets of MZT in exchange for 616,671 Inverness. Based on the Waltham, Massachusetts firm's closing price on December 12, this gave the shares a total value of $34.7m.
You may also be interested in...
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.